J Virol, February 1998, p. 919-925, Vol. 72, No. 2
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Both the Polycythemia- and Anemia-Inducing Strains
of Friend Spleen Focus-Forming Virus Induce Constitutive Activation of
the Raf-1/Mitogen-Activated Protein Kinase Signal Transduction
Pathway
Karen W.
Muszynski,1
Takashi
Ohashi,2,
Charlotte
Hanson,1 and
Sandra K.
Ruscetti2,*
Intramural Research Support Program, SAIC
Frederick,1 and
Basic Research
Laboratory, DBS,2 National Cancer
Institute-Frederick Cancer Research and Development Center, Frederick,
Maryland 21702-1201
Received 5 August 1997/Accepted 16 October 1997
 |
ABSTRACT |
The erythroleukemia-inducing Friend spleen focus-forming virus
(SFFV) encodes a unique envelope glycoprotein which allows erythroid
cells to proliferate and differentiate in the absence of erythropoietin
(Epo). In an attempt to understand how the virus causes Epo
independence, we have been studying signal transduction pathways
activated by Epo to determine if SFFV exerts its biological effects by
constitutively activating any of these pathways in the absence of Epo.
We previously demonstrated that Stat proteins, the downstream
components of the Epo-induced Jak-Stat pathway, are constitutively
activated in SFFV-infected cells. In this study, we demonstrate that
SFFV also activates Raf-1, MEK and mitogen-activated protein (MAP)
kinase, the downstream components of the Raf-1/MAP kinase pathway. This
pathway was activated in cells infected with the polycythemia-inducing
strain of SFFV, which induces both proliferation and differentiation of
erythroid cells in the absence of Epo, as well as in cells infected
with the anemia-inducing strain of the virus, which still require Epo
for differentiation. Inhibition of Raf-1 by using antisense
oligonucleotides led to a partial inhibition of the Epo-independent
proliferation of SFFV-infected cells. Expression of the transcription
factors c-Jun and JunB, but not c-Fos, was induced in SFFV-infected
cells in the absence of Epo, suggesting that constitutive activation of
the Raf-1/MAP kinase pathway by the virus may result in deregulation of
AP-1 activity. We conclude from our studies that infection of erythroid cells with SFFV leads to the constitutive activation of signal transduction molecules in both the Jak-Stat and Raf-1/MAP kinase pathways and that both of these pathways must be activated to achieve
maximum proliferation and differentiation of erythroid cells in the
absence of Epo.
 |
INTRODUCTION |
Friend spleen focus-forming virus
(SFFV) is a replication-defective retrovirus that induces a rapidly
occurring erythroleukemia in susceptible strains of adult mice (for a
review, see reference 52). Proliferation and
differentiation of normal erythroid cells require stimulation with
erythropoietin (Epo); however, infection with SFFV induces erythroid
cell growth in the absence of Epo (37, 38, 51, 53, 54, 64).
Although all strains of the virus cause erythroleukemia, variants of
the virus differ in their effects on erythroid cell growth. Infection
of mice with the polycythemia-inducing strain of SFFV
(SFFVP) induces Epo-independent proliferation and
differentiation of erythroid cells (22, 26, 35). In
contrast, erythroid cells from mice infected with the anemia-inducing
strain of SFFV (SFFVA) proliferate in the absence of Epo
but still require Epo for differentiation (22, 31, 61, 65).
Previous studies have shown that the unique glycoprotein encoded by the
SFFV envelope gene is responsible for the effects of the virus on
erythroid cell growth (9, 33, 68, 69). Differences in the
biological effects of SFFVP and SFFVA have been
attributed to small sequence differences in the transmembrane region of
the envelope glycoproteins of these two viruses (50, 68).
Further studies indicated that the SFFV envelope protein associates
with the Epo receptor complex at the cell surface and that only cells
expressing an Epo receptor capable of transducing a mitogenic signal
are rendered factor independent by the virus (3, 12, 25, 29,
70). These results suggest that SFFV may affect erythroid cell
growth by activating signal transduction pathways that are normally
activated by interaction of Epo with its cell surface receptor.
Studies have shown that binding of Epo to the Epo receptor activates
two distinct signal transduction pathways: the Jak-Stat pathway
(13, 27, 39) and the Raf-1/mitogen-activated protein kinase
(MAPK) pathway (4, 8, 11, 23, 40). Epo activation of the
Jak-Stat pathway induces phosphorylation of Jak kinases (27)
and activates the DNA-binding activity of Stat family proteins (13, 57). Using the Epo-dependent HCD-57 erythroleukemia
cell line, we previously demonstrated that infection with
SFFVP abrogates Epo dependence in HCD-57 cells
(53) and induces constitutive Stat DNA-binding activity in
the absence of Epo (46). In this study, we sought to
determine if infection with SFFV also induces constitutive activation
of the Raf-1/MAPK signaling pathway.
The Raf-1/MAPK pathway is a growth factor-activated signal transduction
pathway that also transduces signals from the cell surface to the
nucleus (49). Ligand stimulation of growth factor receptors,
including the Epo receptor, induces phosphorylation and activation of
the Raf-1 serine/threonine kinase by activating Ras GTP-binding
activity (17, 34, 58). Ras-GTP then recruits Raf-1 to the
cell membrane, where it is phosphorylated and activated by other
kinases (62). Activated Raf-1 phosphorylates and activates MAPK kinase (MEK) (16, 32), which phosphorylates and
activates MAPK (10). The targets of activated MAPK include
transcription factors that regulate the expression or activity of
immediate-early response genes including c-myc
(21) and components of the AP-1 transcription factor
complex, c-fos (20, 63), c-jun
(7, 48), and junB (24).
To determine if SFFV activates the Raf-1/MAPK pathway, we evaluated the
effect of SFFV on Raf-1, MEK, and MAPK activity in HCD-57 cells
infected with SFFVP or SFFVA. In addition, we
analyzed the virus-infected cells for expression of immediate-early
response genes whose transcription is induced by Epo or whose activity is regulated by MAPK-mediated posttranslational control. Our results indicate that infection of erythroid cells with SFFV induces
constitutive activation of the downstream components of the Raf-1/MAPK
pathway and deregulates expression of the Jun component of the AP-1
transcription factor complex. In addition, using c-raf
antisense oligonucleotides to inhibit Raf-1 expression, we have also
determined that Epo-independent activation of the Raf-1/MAPK pathway
alone is not sufficient to induce growth factor-independent
proliferation of SFFV-infected erythroid cells.
 |
MATERIALS AND METHODS |
Cell lines.
HCD-57 cells are Epo-dependent erythroleukemia
cells derived from an NIH Swiss mouse infected with Friend murine
leukemia virus at birth (53, 60). HCD-57 cells were
maintained in Iscove's modified Dulbecco minimal essential medium
(DMEM) supplemented with 30% fetal calf serum (FCS), 5 × 10
5 M 2-mercaptoethanol, penicillin (100 U/ml),
streptomycin (100 µg/ml), L-glutamine, (3 mg/ml) and Epo
(0.3 U/ml) in 5% CO2 at 37°C. HCD-57 cells in which Epo
dependence had been abrogated by infection with SFFVP or
SFFVA (53) were maintained in the same medium
without Epo. The Epo used was a tissue culture supernatant from
fibroblasts that had been transfected with the human Epo gene as
previously described (53).
Cell lysates and immunoprecipitation.
To prepare cell
lysates, cells grown to a density of 106 cells/ml in DMEM
were washed twice in medium without serum and incubated in medium plus
1.5% serum at 37°C in 5% CO2 overnight (12 to 15 h). The next day, cells were centrifuged at 1,200 × g
for 5 min and resuspended in fresh medium plus 1.5% serum and starved
for an additional 2 h at 37°C in 5% CO2. Epo was
added to the Epo-stimulated cells at a concentration of 0.3 U/ml for 15 min. Cells were then centrifuged at 1,200 × g for 5 min, and the pellet was washed twice with ice-cold phosphate-buffered
saline containing 1.0 mM Na3VO4. Cells were
resuspended in 1 ml of lysis buffer (20 mM Tris [pH 7.4], 150 mM
NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, 2 mM
NaPPi, 2 mM NaF, 0.5 mM phenylmethylsulfonyl fluoride, 1 µg each of aprotinin and leupeptin per ml, 1 mM
Na3VO4). Insoluble material was removed by
centrifugation at 12,000 × g at 4°C for 20 min, and
protein concentrations were determined by using a Bio-Rad Laboratories
(Hercules, Calif.) protein assay kit. For immunoprecipitation, 1 mg of
protein was incubated for 2 h at 4°C with a Raf-1-specific
monoclonal antibody (Transduction Laboratories, Lexington, Ky.),
anti-MEK purified polyclonal antibody (C-18; Santa Cruz Biotechnology,
Inc., Santa Cruz, Calif.), or purified Erk-2 polyclonal antibody (C-14;
Santa Cruz Biotechnology). The antigen-antibody complexes were
collected with protein A-agarose beads (Gibco-BRL, Gaithersburg, Md.).
Western blot analysis and Raf-1 coupled-kinase assay.
The
phosphorylation-induced shift in the molecular weight of Raf-1 was
assayed by Western blot analysis. Specifically, immunoprecipitated Raf-1 conjugated to protein A-agarose beads was washed three times with
TBST (50 mM Tris-HCl [pH 7.3], 150 mM NaCl, 0.05% Tween 20), resuspended in protein loading buffer, and boiled for 5 min at 95°C.
Proteins were resolved by electrophoresis on a sodium dodecyl sulfate
(SDS)-7.5% polyacrylamide gel and blotted onto nitrocellulose. Blots
were blocked with 5% nonfat milk in TBST plus 2% Tween 20 for 30 min
and incubated with anti-Raf antibody at room temperature for 1 h.
Blots were then washed three times with TBST plus 2% Tween 20 and
incubated with an anti-mouse immunoglobulin G antibody conjugated to
horseradish peroxidase (Amersham Corp., Arlington Heights, Ill.) for 30 min at room temperature. Blots were washed three times with TBST plus
2% Tween 20, and protein bands were detected by enhanced
chemiluminescence (Amersham).
The coupled-kinase assay was performed as described by Alessi et al.
(1), with minor modifications. Briefly, Raf-1
immunoprecipitates were washed as previously described (1)
and incubated for 30 min at 30°C in kinase reaction buffer (50 mM
Tris-HCl [pH 7.4], 0.03 Brij 35, 0.1 mM EGTA, 0.1%
2-mercaptoethanol, 0.66 µM okadaic acid, 0.27 mM
Na3VO4, 13.3 mM magnesium acetate, 0.33 mM ATP) containing 0.4 µg of glutathione S-transferase (GST)-MEK
(Upstate Biotechnology, Inc. [UBI], Lake Placid, N.Y.) and 1.5 µg
of GST-MAPK (UBI). Two microliters of this reaction mixture was added
to a second kinase reaction buffer (25 mM Tris-HCl, pH 7.0, 0.1 mM EGTA, 10 mM magnesium acetate) containing 10 µCi of
[
-32P]ATP and 3.3 mg of myelin basic protein (MBP;
Gibco-BRL) and incubated for 10 min at 30°C. Two control reactions
were carried out in which either GST-MEK or the Raf-1
immunoprecipitates were replaced with kinase buffer. The reaction was
stopped by pipetting 40 µl of the reaction onto phosphocellulose
filters. The filters were washed twice with 0.8% phosphoric acid and
twice with H2O. The incorporation of 32P into
MBP was measured by scintillation counting. To determine the amount of
Raf-1 in the reaction, a 20-µl aliquot of the immunoprecipitated protein was taken after the wash steps, resuspended in protein loading
buffer, resolved on a 7.5% gel, and detected by Western analysis using
the anti-Raf-1 antibody as described above.
Immune complex kinase assays.
Immunoprecipitated proteins
conjugated to protein A-agarose beads were washed twice in lysis buffer
and twice in kinase buffer (20 mM Tris-HCl [pH 7.4], 20 mM NaCl, 10 mM Mg2Cl, 1 mM dithiothreitol). For Raf-1 kinase assays,
immunoprecipitated Raf-1 was resuspended in 35 µl of kinase buffer
containing 10 µM ATP, 20 µCi of [Y-32P]ATP, and 2 µg of GST-kinase-inactive (K97A) MEK (MEK
) (UBI). MEK
and MAPK activities were assayed in 35 µl of kinase buffer containing
10 µM ATP, 20 µCi of [Y-32P]ATP, 1 µg of leupeptin
per ml, and 1 µM okadaic acid. As substrates, 5 µg of
GST-kinase-inactive (K71A) MAPK (MAPK
) (UBI) was added
to the MEK kinase reaction mixture and 4 µg of MBP was added to the
MAPK kinase assay. Reaction mixtures were incubated for 30 min at
30°C. The reactions were stopped with protein loading buffer, and
reaction mixtures were boiled for 5 min at 95°C. Proteins were
resolved on SDS-polyacrylamide gels and transferred to nitrocellulose.
Phosphorylated substrate bands were visualized by autoradiography.
Proteins were analyzed by Western blot analysis as described above.
Western blot analysis of MAPK.
For Western blot analysis of
MAPK, cells starved and stimulated with Epo as described above were
resuspended in 100 µl of SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 50 mM dithiothreitol, 0.1% bromophenol blue)
and sonicated for 10 to 15 s to reduce sample viscosity. Samples
were then heated at 95°C for 5 min and cooled on ice. Proteins were
resolved on a 4 to 20% gel by SDS-polyacrylamide gel electrophoresis
and transferred electrophoretically to nitrocellulose membranes. The
blots were blocked with 5% nonfat milk in TBST buffer at room
temperature for 2 h and then incubated overnight at 4°C with a
phosphospecific p42/44 MAPK antibody (New England Biolabs, Inc.,
Beverly, Mass.). The blot was washed three times with TBST and
incubated with anti-mouse immunoglobulin G conjugated to horseradish
peroxidase for 1 h at room temperature. The blot was washed three
times with TBST, and protein bands were detected by using a Phototope
Western detection kit (New England Biolabs). The blot was stripped and
reprobed with an antibody that recognizes both phosphorylated and
unphosphorylated p42/44 MAPK (New England Biolabs).
Northern analysis.
For Northern analysis of RNA, total RNA
was extracted from cells by using RNA STAT-60 (Tel-Test "B,"
Friendswood, Tex.) according to the manufacturer's protocol. Twenty
micrograms of RNA was subjected to formalin-agarose gel
electrophoresis, transferred to a nitrocellulose filter, and hybridized
with probes specific for c-myc (1.5-kb fragment containing
exons 2 and 3, from L. Wolff, National Cancer Institute, Bethesda,
Md.), c-fos (1.7-kb fragment cloned into pUC18, from D. Blair, National Cancer Institute, Frederick, Md.), c-jun
(mouse oligonucleotide ON254; Oncogene Research Products, Cambridge,
Mass.), or junB (American Type Culture Collection, Rockville, Md.). Hybridization was carried out at 68°C for 1 h in a hybridization oven, using Stratagene's Quik Hybe solution. Filters were washed two times at 68°C for 10 min in 2× SSC (1× SSC
is 0.15 M NaCl plus 0.15 M sodium citrate) plus 0.1% SDS. The filters
were then stripped and reprobed with a
-actin probe (mouse
oligonucleotide ON365; Oncogene Research Products) under the same
conditions with two additional washes.
Antisense assay.
Cells were treated with a phosphorothioate
antisense (5'-TCCCTGTATGTGCTCCAT-3') or sense
(5'-ATGGAGCACATACAGGGA-3') oligonucleotide synthesized by
the phosphoramadite method on an automated synthesizer (Applied
Biosystems, Foster City, Calif.), and the effect of each oligonucleotide on cell proliferation was analyzed by using
[3H]thymidine incorporation assays as previously
described (42, 43). Briefly, SFFV-infected and uninfected
HCD-57 cells were washed twice, and 5 × 103
cells/well were seeded in 96-well plates in 100 µl of DMEM plus 10%
FCS and incubated for 8 h in the presence of 2.0 µM
c-raf antisense or sense oligonucleotide at 37°C in 5%
CO2. Cells growing in medium alone or in medium plus Epo
were used as controls. After 8 h, a second 2.0 µM aliquot of
oligonucleotides was added, and cells were either stimulated with Epo
(0.3 U/ml) or grown in the absence of Epo for 42 h at 37°C in
5% CO2. Cells were then pulsed with 1 µCi of
[3H]thymidine for 6 h. Cells were harvested onto
glass filters, and [3H]thymidine incorporation was
measured by scintillation counting.
 |
RESULTS |
Infection with SFFV constitutively activates Raf-1 in HCD-57
cells.
It has been previously demonstrated that Raf-1 is activated
by phosphorylation in response to Epo stimulation of HCD-57 cells (8). Phosphorylation of Raf-1 induces a change in its
molecular weight which can be detected by a shift in the
electrophoretic mobility of the protein (41). To determine
if infection with SFFV activates the Raf-1/MAPK pathway, we initially
evaluated the effect of the virus on the electrophoretic mobility of
Raf-1 purified from HCD-57 cells infected with either SFFVP
or SFFVA (53). Uninfected HCD-57 cells and
HCD-57 cells infected with either SFFVP or
SFFVA were starved for growth factor overnight and then
stimulated in complete medium with or without Epo for 15 min. As shown
in Fig. 1, the electrophoretic mobility
of Raf-1 was shifted in SFFVP- and
SFFVA-infected cells after starvation (lanes 2 and 6) or
incubation in complete medium without Epo (lanes 3 and 7). Stimulation
with Epo did not induce any additional changes in the mobility of Raf-1
(lanes 4 and 8). In comparison, only the unshifted
lower-molecular-weight form of Raf-1 was detected in unstimulated
HCD-57 cells which did not express the virus (lanes 1 and 5).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 1.
Infection with SFFV alters the electrophoretic mobility
of Raf-1 in HCD-57 cells. Raf-1 was immunoprecipitated from uninfected
(lanes 1 and 5), SFFVP-infected (lanes 2 and 4), or
SFFVA-infected (lanes 6 and 8) HCD-57 cells after
starvation in 1.5% FCS overnight or after incubation of the starved
cells for 15 min in complete medium with (lanes 3 and 7) or without
(lanes 4 and 8) Epo. The immunoprecipitated proteins were resolved by
electrophoresis on an SDS-7.5% polyacrylamide gel and detected by
Western blotting using an anti-Raf-1 monoclonal antibody.
|
|
To determine if the SFFV-induced shift in Raf-1 mobility was associated
with an increase in Raf-1 kinase activity, Raf-1 activation was first
evaluated in immune complex kinase assays using GST-MEK
as a substrate. In contrast to Epo-induced activation of Raf-1 in
uninfected HCD-57 cells, Raf-1 was constitutively activated in HCD-57
cells infected with either SFFVP or SFFVA (Fig.
2A). The addition of Epo did not result
in a reproducible increase in Raf-1 kinase activity in the
SFFV-infected cells (Fig. 2A).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 2.
Infection with SFFV leads to constitutive activation of
Raf-1 in HCD-57 cells. Raf-1 immunoprecipitates from uninfected and
SFFV-infected HCD-57 cells that had been starved overnight in 1.5% FCS
and either left unstimulated ( ) or stimulated with Epo for 15 min (+)
were assayed for Raf-1 kinase activity. (A) Immune complex kinase assay
measuring incorporation of 32P into GST-MEK .
Phosphorylation of MEK was detected by autoradiography.
The filter was then probed with an anti-Raf-1 antibody to visualize the
total amount of Raf-1 present in the kinase reaction. (B)
Coupled-kinase assay measuring Raf-1 activation of MAPK, using
exogenous GST-MEK and GST-MAPK as substrates. Activation of GST-MAPK by
Raf-1 was assayed by phosphorylation of MBP. Specific incorporation of
32P into MBP was measured by scintillation counting.
Results are reported after substraction of values obtained from control
reactions in which either the MEK substrate or Raf-1 was not included
in the reaction mixture. The amount of Raf-1 in the assay was
visualized by Western blot analysis of the immunoprecipitated protein
with anti-Raf-1 antibody.
|
|
Growth factor-induced activation of Raf-1 initiates a kinase cascade in
which Raf-1 phosphorylates and activates MEK (16, 32), which
in turn phosphorylates and activates MAPK (10). To determine
if the SFFV-induced phosphorylation of MEK observed in the immune
complex kinase assays (Fig. 2A) was coupled to activation of downstream
subtrates in the kinase cascade, Raf-1 activity was further evaluated
in a linked kinase cascade assay measuring phosphorylation of MBP in
the presence of GST-MEK and GST-MAPK (Fig. 2B). Consistent with results
from the immune complex kinase assays (Fig. 2A), immunoprecipitates of
Raf-1 from both unstimulated and Epo-stimulated SFFV-infected cells
induced phosphorylation of MBP in the coupled kinase assay, while
Raf-1-induced phosphorylation of MBP was observed only in uninfected
HCD-57 cells following stimulation with Epo (Fig. 2B). These results
indicate that unlike uninfected HCD-57 cells, Raf-1 is constitutively
activated in HCD-57 cells infected with SFFV. There was no detectable
difference between the effects of SFFVP and
SFFVA on Raf-1 activation.
MEK is constitutively activated in SFFV-infected cells.
Although the coupled kinase assay demonstrates that SFFV-induced
activation of Raf-1 is sufficient for activation of the downstream substrates in the Raf-1/MAPK pathway in vitro, it does not prove that
Raf-1 constitutively activates the downstream substrates in this
pathway in SFFV-infected cells. Therefore, we evaluated MEK kinase
activity in the virus-infected cell lines in immune complex kinase
assays using MAPK
as a substrate (Fig.
3). Consistent with SFFV-induced
activation of Raf-1, MEK was constitutively activated in
SFFVP- and SFFVA-infected HCD-57 cells, while
uninfected HCD-57 cells required Epo to activate MEK (Fig. 3).
Stimulation of SFFVA-infected cells with Epo consistently induced a two- to fivefold increase in MEK kinase activity above constitutive levels of activation (Fig. 3), while MEK kinase activity in SFFVP-infected cells was not significantly enhanced by
the addition of Epo (Fig. 3).

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
MEK is constitutively activated in SFFV-infected cells.
MEK was immunoprecipitated from uninfected and SFFV-infected HCD-57
cells that had been starved overnight in 1.5% FCS and either left
unstimulated ( ) or stimulated with Epo for 15 min (+).
Immunoprecipitates were assayed for MEK kinase activity by immune
complex kinase assays measuring incorporation of 32P into
GST-MAPK . Phosphorylation of MAPK was
detected by autoradiography, and the filter was then probed with
anti-MEK antibody to visualize the amount of MEK present in the kinase
reaction.
|
|
MAPK is constitutively phosphorylated and activated in
SFFV-infected cells.
Recent studies have demonstrated that
activated Raf-1 induces activation of MAPK through MEK-mediated
phosphorylation of both tyrosine and serine/threonine residues (5,
10). Therefore, we evaluated the effect of SFFV infection on
phosphorylation and activation of MAPK by using antiphosphotyrosine
blotting (Fig. 4A) and immune complex
kinase assays (Fig. 4B). A Western blot was probed with an anti-MAPK
antibody which specifically recognizes the tyrosine-phosphorylated form
of the 42/44-kDa species of MAPK (Fig. 4A). The
anti-MAPK-phosphotyrosine antibody detected a tyrosine-phosphorylated 42/44-kDa protein in both unstimulated and Epo-stimulated HCD-57 cells
infected with either SFFVP or SFFVA. However,
MAPK was detected by this antibody in uninfected HDC-57 cells only when
the cells were stimulated with Epo (Fig. 4A). To determine if MAPK was
expressed in unstimulated HCD-57 cells, the blot was reprobed with an
anti-MAPK antibody which recognizes both phosphorylated and
unphosphorylated forms of the protein, and MAPK was readily detected in
all of the cell lines (Fig. 4A). Phosphotyrosine-induced activation of MAPK was further evaluated in an immune complex kinase assay using MBP
as a substrate (Fig. 4B). MAPK was activated in response to Epo
stimulation of uninfected HCD-57 cells; however, MAPK was constitutively activated in the SFFV-infected cell lines (Fig. 4B).
Consistent with the enhanced activity of MEK observed when SFFVA-infected cells were stimulated with Epo, a one- to
twofold increase in MAPK activity was detected in Epo-stimulated cells infected with SFFVA.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 4.
MAPK is constitutively phosphorylated and activated in
SFFV-infected cells. (A) Uninfected and SFFV-infected HCD-57 cells
starved overnight in 1.5% FCS and either left stimulated ( ) or
stimulated with Epo for 15 min (+) were resuspended in SDS lysis buffer
and analyzed by Western blot analysis using a phosphospecific anti-MAPK
(p42/44) antibody to detect tyrosine-phosphorylated MAPK (MAPK-PTYR).
The blot was then stripped and reprobed with a p42/44-specific
anti-MAPK antibody that detects both the phosphorylated and
unphosphorylated forms of MAPK. (B) Immunoprecipitated MAPK was assayed
in immune complex kinase assays measuring incorporation of
32P into MBP. Phosphorylation of MBP was detected by
autoradiography, and the filter was then probed with anti-MAPK antibody
to visualize the amount of MAPK present in the kinase reaction. IgG,
immunoglobulin G.
|
|
Expression of c-Jun and JunB but not c-Fos and c-Myc is altered by
SFFV infection.
Epo-induced early-response genes encoding the
transcription factors c-Myc (6, 40, 59) and c-Fos (40,
47, 66) have been identified as targets for receptor tyrosine
kinase-mediated regulation by MAPK (21, 28, 56). Therefore,
we evaluated the expression of c-myc and c-fos in
HCD-57 cells infected with SFFV by Northern analysis (Fig.
5). Transcripts for c-myc were detected in both SFFV-infected and uninfected HCD-57 cells in the
absence of Epo (Fig. 5), indicating that c-myc mRNA is
constitutively expressed in HCD-57 cells and is not induced by
infection with SFFV. In contrast, c-fos was constitutively
expressed at low levels in both uninfected and SFFV-infected HCD-57
cells, and stimulation with Epo induced an increase in the level of
c-fos mRNA in all three cell lines (Fig. 5). Interestingly,
the level of c-fos transcription induced by Epo was
significantly less in SFFV-infected cells than in uninfected cells
stimulated with Epo (Fig. 5).

View larger version (70K):
[in this window]
[in a new window]
|
FIG. 5.
Infection with SFFV does not alter c-fos or
c-myc expression in HCD-57 cells. Uninfected and
SFFV-infected HCD-57 cells were starved overnight in 1.5% FCS and
either left unstimulated ( ) or stimulated for 15 min with Epo (+).
RNA was extracted and analyzed by Northern blotting as described in
Materials and Methods. The filter was sequentially stripped and
reprobed with radiolabeled cDNA probes specific for c-fos,
c-myc, or actin mRNA.
|
|
c-Fos is a component of the AP-1 transcription factor complex, which is
composed of a variety of Jun and Fos homo- and heterodimers which
induce transcription from response elements activated by tetradecanoyl
phorbol acetate and other stimuli, including Epo (15, 28,
47). Since an active AP-1 complex requires expression of
jun family genes (2, 45, 55), we also evaluated
expression of c-jun and junB in virus-infected
and uninfected HCD-57 cells. Previous experiments have indicated that
expression of c-jun is not induced by Epo (6,
47), while Epo-induced expression of junB has not been
evaluated in erythroid cells. Consistent with previous results,
c-jun was not expressed in unstimulated HCD-57 cells, and
transcription was not induced by Epo (Fig.
6). However, c-jun mRNA was
expressed in both unstimulated and Epo-stimulated SFFV-infected cells
(Fig. 6). Furthermore, expression of junB mRNA, which was
induced by Epo in HCD-57 cells, was constitutive in SFFV-infected cells
(Fig. 6). These results demonstrate deregulated expression in
SFFV-infected cells of the genes encoding the c-Jun and JunB components
of the AP-1 complex.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 6.
Infection with SFFV activates transcription of
c-jun and junB in HCD-57 cells. Uninfected and
SFFV-infected HCD-57 cells were starved overnight in 1.5% FCS and
either left unstimulated ( ) or stimulated with Epo for 15 min (+).
RNA was extracted and analyzed by Northern blotting as described in
Materials and Methods. The filters were sequentially probed with
radiolabeled cDNAs specific for either c-jun and
actin (A) or junB and actin (B).
|
|
c-raf antisense oligonucleotides inhibit growth
factor-independent proliferation of SFFV-infected HCD-57 cells.
Previous studies using c-raf antisense oligonucleotides to
inhibit expression of Raf-1 have demonstrated that Raf-1 is required for growth factor-induced proliferation of factor-dependent cell lines,
including HCD-57 cells (8, 43). Therefore, we used previously characterized c-raf antisense oligonucleotides
(8, 42, 43) to evaluate the requirement for Raf-1 in
SFFV-induced growth factor-independent proliferation of HCD-57 cells
(Fig. 7). Identical to the results of our
previous study (43), c-raf antisense
oligonucleotides inhibited Epo-induced proliferation of uninfected
HCD-57 cells by 87%, while sense oligonucleotides had little or no
effect on cell growth (Fig. 7). Treatment with c-raf
antisense oligonucleotides inhibited the Epo-independent proliferation
of HCD-57 cells infected with SFFVP by 58% and inhibited proliferation of HCD-57 cells infected with SFFVA by 65%,
while sense oligonucleotides had no significant effect (Fig. 7). In contrast to SFFVP-infected cells, cells infected with
SFFVA proliferate better in the presence of Epo
(48). Therefore, we also evaluated the effect of
c-raf antisense oligonucleotides on Epo-induced proliferation of SFFVA-infected HCD-57 cells. As shown in
Fig. 7, c-raf antisense oligonucleotides inhibited the
Epo-induced proliferation of SFFVA-infected cells by 60%,
similar to their effect on unstimulated cells. These results
demonstrate that the requirement for Raf-1 in Epo-induced proliferation
of HCD-57 cells is partially abrogated by infection with SFFV.

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 7.
c-raf antisense oligonucleotides inhibit
Epo-independent proliferation of HCD-57 cells infected with SFFV.
Uninfected and SFFV-infected HCD-57 cells were not treated ( ) or
treated with 4.0 µM c-raf antisense ( ) or sense ( )
oligonucleotide in the presence or absence of Epo and assayed for
[3H]thymidine incorporation as described in Materials and
Methods.
|
|
 |
DISCUSSION |
In this study, we have determined that infection of the murine
erythroleukemia cell line HCD-57 with SFFV induces constitutive activation of the major downstream components of the Raf-1/MAPK signal
transduction pathway. Raf-1 kinase activity, which is activated by Epo
in uninfected HCD-57 cells, is constitutively activated in HCD-57 cells
infected with either the SFFVP or SFFVA variant of the virus. Consistent with this result, MEK, a direct substrate of
Raf-1, and MAPK, the downstream effector molecule in this pathway, were
also constitutively activated in both SFFVP- and
SFFVA-infected HCD-57 cells.
Although erythroid cells infected with SFFVP and
SFFVA differ in the ability to differentiate in the absence
of Epo, both viruses were shown in this study to constitutively
activate the Raf-1/MAPK pathway in HCD-57 cells, a result that we have
recently confirmed in studies using spleen cells from virus-infected
mice (46a). This finding suggests that constitutive
activation of the Raf-1/MAPK pathway is not sufficient to induce
Epo-independent differentiation of erythroid cells. In contrast,
constitutive activation of the Jak-Stat pathway by SFFV appears to be
required to achieve differentiation of erythroid cells in the absence
of Epo (46a).
Since growth factor activation of the Raf-1/MAPK pathway has been
linked to activation of the immediate-early gene response, we also
evaluated the effect of SFFV infection on expression of several
immediate-early genes, including c-myc, c-fos,
c-jun, and junB. The c-myc gene was
constitutively expressed in both uninfected and SFFV-infected HCD-57
cells; however, only SFFV-infected HCD-57 cells were growth factor
independent. These results are consistent with those of previous
studies demonstrating that coexpression of v-myc and a
constitutively activated v-raf gene renders erythroid cells
growth factor independent, while constitutive expression of either gene
alone is insufficient for the abrogation of growth factor dependence
(30).
The Raf-1/MAPK pathway is thought to regulate c-fos gene
expression by inducing MAPK-mediated phosphorylation of Elk-1, a ternary-complex transcription factor that activates the
c-fos promoter (20, 63). However, no differences
were seen in the level of c-fos expression in uninfected or
SFFV-infected HCD-57 cells, despite the fact that the Raf-1/MAPK
pathway was constitutively activated in the latter cells. This finding
suggests that the Raf-1/MAPK pathway is not involved in regulating
c-fos expression in HCD-57 cells. Activation of the Jak-Stat
pathway also does not appear to be regulating c-fos
expression in these cells since previous data indicated constitutive
binding of Stat proteins to the sis-inducible element from
the c-fos promoter in HCD-57 cells infected with
SFFVP (46). Recent studies have identified several other MAPK-related kinases that are involved in the regulation of growth factor-induced activation of c-fos transcription
(28), and these kinases may be activated in SFFV-infected
HCD-57 cells.
The active form of the AP-1 transcription factor consists of hetero- or
homodimers of Fos and Jun family proteins. Jun family proteins can form
homodimers or heterodimers with other Jun family members, but c-Fos
alone cannot dimerize and does not bind DNA or activate transcription
in the absence of Jun (2). In contrast to uninfected HCD-57
cells, which failed to express c-jun and expressed
junB only after Epo stimulation, SFFV-infected cells constitutively expressed both c-jun and junB,
suggesting that SFFV may affect AP-1 activity by deregulating
expression of jun family genes. Studies are in progress to
evaluate this possibility.
Transcriptional activation of c-jun is autoregulated, and a
distinct signal transduction pathway has recently been identified which
leads to the activation of Jun kinases (JNKs), which in turn
phosphorylate and activate c-Jun (32, 36). The pathway leading to JNK activation has been called the stress-activated protein
kinase (SAPK) pathway because it is primarily activated by cell
stressors such as UV irradiation, which are poor activators of the
Raf-1/MAPK pathway (32). However, the JNK/SAPK
pathway is also activated by a variety of growth factors, including Epo (15, 18, 44). In addition, constitutively activated
MEK can activate JNK and stimulate c-Jun-mediated-transcription
(19), suggesting that there is cross talk between
the Raf-1/MAPK and the JNK/SAPK signal transduction pathways. Since
c-jun and junB are constitutively expressed in
SFFV-infected cells, we are currently evaluating the effect of SFFV
infection on activation of the JNK/SAPK signal transduction pathway in
HCD-57 cells.
The requirement for an intact Raf-1/MAPK pathway in growth
factor-induced proliferation has been demonstrated in a number of
different experimental systems (14). As previously shown (8, 43), c-raf antisense inhibition of Raf-1
expression in HCD-57 cells almost completely inhibited their
proliferation in response to Epo. However, SFFV-infected HCD-57 cells
treated with c-raf antisense oligonucleotides could still
proliferate in the absence of Epo, although at reduced levels. Our data
suggest that Raf-1 is not essential for the Epo-independent
proliferation of SFFV-infected HCD-57 cells per se but rather
cooperates with other signal transduction pathways to achieve maximum
proliferation of SFFV-infected HCD-57 cells in the absence of Epo. One
such cooperating pathway is likely to be the Jak-Stat pathway, since our previous studies demonstrated constitutive activation of Stat transcription factors in SFFV-infected erythroid cells (46). Studies are in progress to assess the effects of inhibiting Stat activation on Epo-independent proliferation of SFFV-infected cells.
We conclude from our studies that infection of erythroid cells with
SFFV leads to the constitutive activation of the Raf-1/MAPK pathway and
that activation of this pathway is required to achieve maximum
proliferation of erythroid cells in the absence of Epo. Studies are in
progress to examine SFFV-infected erythroid cells for activation of
upstream components in the Raf-1/MAPK pathway to better understand how
interaction of the SFFV envelope glycoprotein with the Epo receptor
leads to activation of the downstream components of this pathway. In
addition, we have initiated studies to determine if there is
convergence between SFFV-induced activation of the Raf-1/MAPK and
Jak-Stat signal transduction pathways.
 |
ACKNOWLEDGMENTS |
We thank D. Blair and L. Wolff for kindly providing some of the
cDNA probes used in this study, G. Heidecker for the gift of
GST-MEK
, and Karen Cannon for helpful assistance in the
preparation of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Basic Research
Laboratory, DBS, NCI-FCRDC, P.O. Box B, Frederick, MD 21702-1201. Phone: (301) 846-1586. Fax: (301) 846-6164. E-mail:
ruscetti{at}ncifcrf.gov.
Present address: Department of Immunotherapeutics, Tokyo Medical
and Dental University, Tokyo, Japan.
 |
REFERENCES |
| 1.
|
Alessi, D. R.,
P. Cohen,
A. Ashworth,
S. Cowley,
S. J. Leevers, and C. J. Marshall.
1995.
Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf.
Methods Enzymol.
255:279-290[Medline].
|
| 2.
|
Angel, P., and M. Karin.
1991.
The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation.
Biochim. Biophys. Acta
1072:129-157[Medline].
|
| 3.
|
Barber, D. L.,
J. C. DeMartino,
M. O. Showers, and A. D. D'Andrea.
1994.
A dominant negative erythropoietin (EPO) receptor inhibits EPO-dependent growth and blocks F-gp55-dependent transformation.
Mol. Cell. Biol.
14:2257-2265[Abstract/Free Full Text].
|
| 4.
|
Barber, D. L.,
C. N. Corless,
K. Xia,
T. M. Roberts, and A. D. D'Andrea.
1997.
Erythropoietin activates Raf1 by an Shc-independent pathway in CTLL-EPO-R cells.
Blood
89:55-64[Abstract/Free Full Text].
|
| 5.
|
Blumer, K. J., and G. L. Johnson.
1994.
Diversity in function and regulation of MAP kinase pathways.
Trends Biochem. Sci.
19:236-240[Medline].
|
| 6.
|
Bondurant, M. C.,
T. Yamashita,
K. Muta,
S. B. Krantz, and M. J. Koury.
1996.
c-myc expression affects proliferation but not terminal differentiation or survival of explanted erythroid progenitor cells.
J. Cell. Physiol.
168:255-263[Medline].
|
| 7.
|
Cano, E., and L. C. Mahadevan.
1995.
Parallel signal processing among mammalian MAPKs.
Trends Biochem. Sci.
20:117-122[Medline].
|
| 8.
|
Carroll, M. P.,
J. L. Spivak,
M. McMahon,
N. Weich,
U. R. Rapp, and W. S. May.
1991.
Erythropoietin induces Raf-1 activation and Raf-1 is required for erythropoietin-mediated proliferation.
J. Biol. Chem.
266:14964-14969[Abstract/Free Full Text].
|
| 9.
|
Casadevall, N.,
C. Lacombe,
O. Muller,
S. Gisselbrecht, and P. Mayeux.
1991.
Multimeric structure of the membrane erythropoietin receptor of murine erythroleukemia cells (Friend cells). Cross-linking of erythropoietin with the spleen focus-forming virus envelope protein.
J. Biol. Chem.
266:16015-16020[Abstract/Free Full Text].
|
| 10.
|
Crews, C. M., and R. L. Erikson.
1992.
Purification of a murine protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product: relationship to the fission yeast byr1 gene product.
Proc. Natl. Acad. Sci. USA
89:8205-8209[Abstract/Free Full Text].
|
| 11.
|
Damen, J. E.,
L. Liu,
R. L. Cutler, and G. Krystal.
1993.
Erythropoietin stimulates the tyrosine phosphorylation of Shc and its association with Grb2 and a 145-Kd tyrosine phosphorylated protein.
Blood
82:2296-2303[Abstract/Free Full Text].
|
| 12.
|
D'Andrea, D. A.,
A. Yoshimura,
H. Youssoufian,
L. I. Zon,
J. W. Koo, and H. F. Lodish.
1991.
The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains.
Mol. Cell. Biol.
11:1980-1987[Abstract/Free Full Text].
|
| 13.
|
Darnell, J. E., Jr.,
I. M. Kerr, and G. R. Stark.
1994.
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.
Science
264:1415-1421[Abstract/Free Full Text].
|
| 14.
|
Daum, G.,
I. Eisenmann-Tappe,
H. W. Fries,
J. Troppmair, and U. R. Rapp.
1994.
The ins and outs of Raf kinases.
Trends Biochem. Sci.
19:474-480[Medline].
|
| 15.
|
Davis, R. J.
1995.
Transcriptional regulation by MAP kinases.
Mol. Reprod. Dev.
42:459-467[Medline].
|
| 16.
|
Dent, P.,
W. Haser,
T. A. Haystead,
L. A. Vincent,
T. M. Roberts, and T. W. Sturgill.
1992.
Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro.
Science
257:1404-1407[Abstract/Free Full Text].
|
| 17.
|
Egan, S. E.,
B. W. Giddings,
M. W. Brooks,
L. Buday,
A. M. Sizeland, and R. A. Weinberg.
1993.
Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation.
Nature
363:45-51[Medline].
|
| 18.
|
Foltz, I. N., and J. W. Schrader.
1997.
Activation of the stress-activated protein kinases by multiple hematopoietic growth factors with the exception of interleukin-4.
Blood
89:3092-3096[Abstract/Free Full Text].
|
| 19.
|
Franklin, C. C., and A. S. Kraft.
1995.
Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in U937 human leukemic cells.
Oncogene
11:2365-2374[Medline].
|
| 20.
|
Gille, H.,
A. D. Sharrocks, and P. E. Shaw.
1992.
Phosphorylation of transcription factor p62TCF by MAP kinase stimulates ternary complex formation at c-fos promoter.
Nature
358:414-417[Medline].
|
| 21.
|
Gupta, S., and R. J. Davis.
1994.
MAP kinase binds to the NH2-terminal activation domain of c-Myc.
FEBS Lett.
353:281-285[Medline].
|
| 22.
|
Hankins, W. D.
1983.
Increased erythropoietin sensitivity after in vitro transformation of hematopoietic precursors by RNA tumor viruses.
J. Natl. Cancer Inst.
70:725-734.
|
| 23.
|
He, T.-C.,
N. Jiang,
H. Zhuang, and D. M. Wojchowski.
1995.
Erythropoietin-induced recruitment of Shc via a receptor phosphotyrosine-independent, Jak2-associated pathway.
J. Biol. Chem.
270:11055-11061[Abstract/Free Full Text].
|
| 24.
|
Hipskind, R. A.,
M. Baccarini, and A. Nordheim.
1994.
Transient activation of RAF-1, MEK, and ERK2 coincides kinetically with ternary complex factor phosphorylation and immediate-early gene promoter activity in vivo.
Mol. Cell. Biol.
14:6219-6231[Abstract/Free Full Text].
|
| 25.
|
Hoatlin, M. E.,
S. L. Kozak,
F. Lilly,
A. Chakraborti,
C. A. Kozak, and D. Kabat.
1990.
Activation of erythropoietin receptors by Friend viral gp55 and by erythropoietin and down-modulation by the murine Fv-2r resistance gene.
Proc. Natl. Acad. Sci. USA
87:9985-9989[Abstract/Free Full Text].
|
| 26.
|
Horoszewicz, J. S.,
S. S. Leong, and W. A. Carter.
1975.
Friend leukemia: rapid development of erythropoietin-independent hematopoietic precursors.
J. Natl. Cancer Inst.
54:265-267.
|
| 27.
|
Ihle, J. N.,
B. A. Witthuhn,
F. W. Quelle,
O. Silvennoinen,
B. Tang, and T. Yi.
1994.
Protein tyrosine phosphorylation in the regulation of hematopoiesis by receptors of the cytokine-receptor superfamily.
Blood Cells
20:65-80[Medline].
|
| 28.
|
Karin, M.
1995.
The regulation of AP-1 activity by mitogen-activated protein kinases.
J. Biol. Chem.
270:16483-16486[Free Full Text].
|
| 29.
|
Kishi, A.,
T. Chiba,
M. Sugiyama,
M. Machide,
Y. Nagata,
H. Amanuma,
H. Taira,
T. Katsumata, and K. Todokoro.
1993.
Erythropoietin receptor binds to Friend virus gp55 through other membrane components.
Biochem. Biophys. Res. Commun.
192:1131-1138[Medline].
|
| 30.
|
Klinken, S. P.,
U. R. Rapp, and H. C. Morse, III.
1989.
raf/myc-infected erythroid cells are restricted in their ability to terminally differentiate.
J. Virol.
63:1489-1492[Abstract/Free Full Text].
|
| 31.
|
Koury, M. J.,
M. C. Bondurant,
D. T. Duncan,
S. B. Krantz, and W. D. Hankins.
1982.
Specific differentiation events induced by erythropoietin in cells infected in vitro with the anemia strain of Friend virus.
Proc. Natl. Acad. Sci. USA
79:635-639[Abstract/Free Full Text].
|
| 32.
|
Kyriakis, J. M.,
H. App,
X. F. Zhang,
P. Banerjee,
D. L. Brautigan,
U. R. Rapp, and J. Avruch.
1992.
Raf-1 activates MAP kinase-kinase.
Nature
358:417-421[Medline].
|
| 33.
|
Li, J. P.,
D. A. AD,
H. F. Lodish, and D. Baltimore.
1990.
Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor.
Nature
343:762-764[Medline].
|
| 34.
|
Li, N.,
A. Batzer,
R. Daly,
V. Yajnik,
E. Skolnik,
P. Chardin,
D. Bar-Sagi,
B. Margolis, and J. Schlessinger.
1993.
Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signaling.
Nature
363:85-88[Medline].
|
| 35.
|
Liao, S. K., and A. A. Axelrad.
1975.
Erythropoietin-independent erythroid colony formation in vitro by hemopoietic cells of mice infected with Friend virus.
Int. J. Cancer
15:467-482[Medline].
|
| 36.
|
Minden, A.,
A. Lin,
M. McMahon,
C. Lange-Carter,
B. Derijard,
R. J. Davis,
G. L. Johnson, and M. Karin.
1994.
Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK.
Science
266:1719-1723[Abstract/Free Full Text].
|
| 37.
|
Mirand, E. A.
1967.
Virus-induced erythropoiesis in hypertransfused-polycythemic mice.
Science
156:832-833[Abstract/Free Full Text].
|
| 38.
|
Mirand, E. A.,
R. A. Steeves,
R. D. Lange, and J. T. Grace, Jr.
1968.
Virus-induced polycythemia in mice: erythropoiesis without erythropoietin.
Proc. Soc. Exp. Biol. Med.
128:844-849[Medline].
|
| 39.
|
Miura, O.,
N. Nakamura,
F. W. Quelle,
B. A. Witthuhn,
J. N. Ihle, and N. Aoki.
1994.
Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo.
Blood
84:1501-1507[Abstract/Free Full Text].
|
| 40.
|
Miura, Y.,
O. Miura,
J. N. Ihle, and N. Aoki.
1994.
Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor.
J. Biol. Chem.
269:29962-29969[Abstract/Free Full Text].
|
| 41.
|
Morrison, D. K.,
D. R. Kaplan,
U. Rapp, and T. M. Roberts.
1988.
Signal transduction from membrane to cytoplasm: growth factors and membrane-bound oncogene products increase Raf-1 phosphorylation and associated protein kinase activity.
Proc. Natl. Acad. Sci. USA
85:8855-8859[Abstract/Free Full Text].
|
| 42.
|
Muszynski, K. W.,
F. W. Ruscetti,
J. M. Gooya,
D. M. Linnekin, and J. R. Keller.
1997.
Raf-1 protein is required for growth factor-induced proliferation of primitive hematopoietic progenitors stimulated with synergistic combinations of cytokines.
Stem Cells
15:63-72[Abstract/Free Full Text].
|
| 43.
|
Muszynski, K. W.,
F. W. Ruscetti,
G. Heidecker,
U. Rapp,
J. Troppmair,
J. M. Gooya, and J. R. Keller.
1995.
Raf-1 protein is required for growth factor-induced proliferation of hematopoietic cells.
J. Exp. Med.
181:2189-2199[Abstract/Free Full Text].
|
| 44.
|
Nagata, Y.,
E. Nishida, and K. Todokoro.
1997.
Activation of JNK signaling pathway by erythropoietin, thrombopoietin, and interleukin-3.
Blood
89:2664-2669[Abstract/Free Full Text].
|
| 45.
|
Nakabeppu, Y.,
K. Ryder, and D. Nathans.
1988.
DNA binding activities of three murine Jun proteins: stimulation by Fos.
Cell
55:907-915[Medline].
|
| 46.
|
Ohashi, T.,
M. Masuda, and S. K. Ruscetti.
1995.
Induction of sequence-specific DNA-binding factors by erythropoietin and the spleen focus-forming virus.
Blood
85:1454-1462[Abstract/Free Full Text].
|
| 46a.
| Ohashi, T., et al. Unpublished data.
|
| 47.
|
Patel, H. R., and A. J. Sytkowski.
1995.
Erythropoietin activation of AP1 (Fos/Jun).
Exp. Hematol.
23:619-625[Medline].
|
| 48.
|
Pulverer, B. J.,
J. M. Kyriakis,
J. Avruch,
E. Nikolakaki, and J. R. Woodgett.
1991.
Phosphorylation of c-jun mediated by MAP kinases.
Nature
353:670-674[Medline].
|
| 49.
|
Rapp, U. R.
1991.
Role of Raf-1 serine/threonine protein kinase in growth factor signal transduction.
Oncogene
6:495-500[Medline].
|
| 50.
|
Ruscetti, S., and L. Wolff.
1985.
Biological and biochemical differences between variants of spleen focus-forming virus can be localized to a region containing the 3' end of the envelope gene.
J. Virol.
56:717-722[Abstract/Free Full Text].
|
| 51.
|
Ruscetti, S. K.
1986.
Employment of a [3H]thymidine-incorporation assay to distinguish the effects of different Friend erythroleukemia-inducing retroviruses on erythroid cell proliferation.
J. Natl. Cancer Inst.
77:241-245.
|
| 52.
|
Ruscetti, S. K.
1995.
Erythroleukaemia induction by the Friend spleen focus-forming virus.
Baillieres Clin. Haematol.
8:225-247[Medline].
|
| 53.
|
Ruscetti, S. K.,
N. J. Janesch,
A. Chakraborti,
S. T. Sawyer, and W. D. Hankins.
1990.
Friend spleen focus-forming virus induces factor independence in an erythropoietin-dependent erythroleukemia cell line.
J. Virol.
64:1057-1062[Abstract/Free Full Text].
|
| 54.
|
Sassa, S.,
F. Takaku, and K. Nakao.
1968.
Regulation of erythropoiesis in the Friend leukemia mouse.
Blood
31:758-765[Abstract/Free Full Text].
|
| 55.
|
Sassone-Corsi, P.,
L. J. Ransone,
W. W. Lamph, and I. M. Verma.
1988.
Direct interaction between fos and jun nuclear oncoproteins: role of the `leucine zipper' domain.
Nature
336:692-695[Medline].
|
| 56.
|
Seth, A.,
E. Alvarez,
S. Gupta, and R. J. Davis.
1991.
A phosphorylation site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression.
J. Biol. Chem.
266:23521-23524[Abstract/Free Full Text].
|
| 57.
|
Silvennoinen, O.,
J. N. Ihle,
J. Schlessinger, and D. E. Levy.
1993.
Interferon-induced nuclear signaling by Jak protein tyrosine kinases.
Nature
366:583-585[Medline].
|
| 58.
|
Simon, M. A.,
G. S. Dodson, and G. M. Rubin.
1993.
An SH3-SH2-SH3 protein is required for p21 Ras1 activation and binds to sevenless and Sos proteins in vitro.
Cell
73:169-177[Medline].
|
| 59.
|
Spangler, R.,
S. C. Bailey, and A. J. Sytkowski.
1991.
Erythropoietin increases c-myc mRNA by a protein kinase C-dependent pathway.
J. Biol. Chem.
266:681-684[Abstract/Free Full Text].
|
| 60.
|
Spivak, J. L.,
T. Pham,
M. Isaacs, and W. D. Hankins.
1991.
Erythropoietin is both a mitogen and a survival factor.
Blood
77:1228-1233[Abstract/Free Full Text].
|
| 61.
|
Steinheider, G.,
H. J. Seidel, and L. Kreja.
1979.
Comparison of the biological effects of anemia inducing and polycythemia inducing Friend virus complex.
Experientia
35:1173-1175[Medline].
|
| 62.
|
Stokoe, D.,
S. G. Macdonald,
K. Cadwallader,
M. Symons, and J. F. Hancock.
1994.
Activation of Raf as a result of recruitment to the plasma membrane.
Science
264:1463-1467[Abstract/Free Full Text].
|
| 63.
|
Su, B., and M. Karin.
1996.
Mitogen-activated protein kinase cascades and regulation of gene expression.
Curr. Opin. Immunol.
8:402-411[Medline].
|
| 64.
|
Tambourin, P., and F. Wendling.
1971.
Malignant transformation and erythroid differentiation by polycythaemia-inducing Friend virus.
Nature New Biol.
234:230-233[Medline].
|
| 65.
|
Tambourin, P. E.,
F. Wendling,
C. Jasmin, and F. Smadja-Joffe.
1979.
The physiopathology of Friend leukemia.
Leuk. Res.
3:117-129[Medline].
|
| 66.
|
Tsuda, H.,
N. Aso,
T. Sawada,
H. Hata,
M. Kawakita,
K. J. Mori, and K. Takatsuki.
1991.
Alteration of nuclear proto-oncogene expression by erythropoietin (Epo) in Epo-responsive murine cell lines.
Int. J. Cell Cloning
9:123-133[Abstract].
|
| 67.
|
Wolff, L., and S. Ruscetti.
1985.
Malignant transformation of erythroid cells in vivo by introduction of a nonreplicating retrovirus vector.
Science
228:1549-1552[Abstract/Free Full Text].
|
| 68.
|
Wolff, L., and S. Ruscetti.
1988.
The spleen focus-forming virus (SFFV) envelope gene, when introduced into mice in the absence of other SFFV genes, induces acute erythroleukemia.
J. Virol.
62:2158-163[Abstract/Free Full Text].
|
| 69.
|
Yoshimura, A.,
G. Longmore, and H. F. Lodish.
1990.
Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity.
Nature
348:647-649[Medline].
|
| 70.
|
Yoshimura, A.,
T. Zimmers,
D. Neumann,
G. Longmore,
Y. Yoshimura, and H. F. Lodish.
1992.
Mutations in the Trp-Ser-X-Trp-Ser motif of the erythropoietin receptor abolish processing, ligand binding, and activation of the receptor.
J. Biol. Chem.
267:11619-11625[Abstract/Free Full Text].
|
J Virol, February 1998, p. 919-925, Vol. 72, No. 2
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.